Mesaj de condoleante Prof.Dr. G.G. Constandache



No comments:

CUM SI DE CE A MURIT ION CREANGA



http://www.istorie-pe-scurt.ro/cum-si-de-ce-a-murit-ion-creanga/
.....Dor de Eminescu.... 

"STIU CA SUNT PROST , DAR CAND MA UIT IMPREJUR , PRIND CURAJ  "
ION CREANGA 

http://www.istorie-pe-scurt.ro/cum-si-de-ce-a-murit-ion-creanga/

No comments:

DARUL MEU DE ASTAZI; My way- Andre Rieu on his violin in New York


https://www.youtube.com/embed/e-y581HdWfY?rel=0
DARUL MEU DE ASTĂZI. O muzică Dumnezeească.
Stai pe spate, închide ochii şi bucură-te
ascultând o muzică Dumnezeească.
Paul Anka, un artist cântăreţ şi compozitor, a scris această piesă muzicală pentru Frank Sinatra.
Doar o vioară poate scoate acest sunet
la fel de frumos ca cel adevărat....
A. Rieu nu de multe ori a cântat la vioară bucăţi întregi, dar de data asta a făcut-o!
Renumitul violonist olandez, dirijor şi compozitor, împreună  cu orchestra sa, a adus un tribut
lui Frank Sinatra cu piesa My Way.
Rieu pe comoara lui - o vioară Stradivarius - la Radio City Music Hall - New York.
"My Way" is a song popularized by Frank Sinatra. Its lyrics were written by Paul Anka and set to music based on the French song "Comme d'habitude" composed in 1967 by Claude François and Jacques Revaux. Anka's English lyrics are unrelated to the original French song.
 
 
No comments:

Andrei Plesu-Religia, şcoala şi dreapta măsură

No comments:

Musik


http://saigonocean.com/NhacNgoaiQuoc.htm
Muzică din toate timpurile pentru melomani.

Se alege usor melodia dorită.

http://saigonocean.com/NhacNgoaiQuoc.htm
No comments:

Calendar ortodox deosebit;Este pana in 2037 !!!



Un calendar ortodox deosebit. De pastrat! Este pana in 2037!!!
Mai  jos este un link unde poti intra si, dand click pe ziua dorita, afli viata
sfintilor din acea zi, pe scurt....
Acest calendar se dovedeste a fi o enciclopedie intreaga, incluzand si
biblia, daca urmaresti toate linkurile.
Sa va fie de folos!


No comments:

Interesting Article from MDLinx

MDLinx  Psychiatry

5 minutes to stay current

Your Article Summary

Antipsychotic treatment and mortality in schizophrenia
Schizophrenia Bulletin, 12/16/14
Torniainen M, et al. – It is generally believed that long–term use of antipsychotics increases mortality and, especially, the risk of cardiovascular death. In this study, among patients with schizophrenia, the cumulative antipsychotic exposure displays a U–shaped curve for overall mortality, revealing the highest risk of death among those patients with no antipsychotic use. These results indicate that both excess overall and cardiovascular mortality in schizophrenia is attributable to other factors than antipsychotic treatment when used in adequate dosages.
Methods
  • The authors identified all individuals in Sweden with schizophrenia diagnoses before year 2006 (N = 21 492), aged 17–65 years, and persons with first-episode schizophrenia during the follow-up 2006–2010 (N = 1230).
  • Patient information was prospectively collected through nationwide registers.
  • Total and cause-specific mortalities were calculated as a function of cumulative antipsychotic exposure from January 2006 to December 2010.

Results
  • Compared with age- and gender-matched controls from the general population (N = 214920), the highest overall mortality was observed among patients with no antipsychotic exposure (hazard ratio [HR] = 6.3, 95% CI: 5.5–7.3), ie, 0.0 defined daily dose (DDD)/day, followed by high exposure (>1.5 DDD/day) group (HR = 5.7, 5.2–6.2), low exposure (<0 data-blogger-escaped-.5="" data-blogger-escaped-3.6="" data-blogger-escaped-3.7="" data-blogger-escaped-4.0="" data-blogger-escaped-4.1="" data-blogger-escaped-and="" data-blogger-escaped-day="" data-blogger-escaped-ddd="" data-blogger-escaped-exposure="" data-blogger-escaped-group="" data-blogger-escaped-li="" data-blogger-escaped-moderate="">
  • High exposure (HR = 8.5, 7.3–9.8) and no exposure (HR = 7.6, 5.8–9.9) were associated with higher cardiovascular mortality than either low exposure (HR = 4.7, 3.7–6.0) or moderate exposure (HR = 5.6, 4.8–6.6).
  • The highest excess overall mortality was observed among first-episode patients with no antipsychotic use (HR = 9.9, 5.9–16.6).



Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Psychiatry

>> Click here to see the complete list
No comments:

Interesting Article from MDLinx

MDLinx  Psychiatry

5 minutes to stay current

Your Article Summary

B vitamins to enhance treatment response to antidepressants in middle-aged and older adults: Results from the B-VITAGE randomised, double-blind, placebo-controlled trial
The British Journal of Psychiatry, 12/10/14
Almeida OP, et al. – The study aimed to determine whether vitamins B6, B12 and folic acid enhance response to antidepressant treatment over 52 weeks. Findings revealed that B vitamins did not increase the 12–week efficacy of antidepressant treatment, but enhanced and sustained antidepressant response over 1 year. Replication of these findings would mandate that treatment guidelines adopt the adjunctive use of B vitamins as a safe and inexpensive strategy to manage major depression in middle–aged and older adults.
Methods
  • Randomised, double-blind, placebo-controlled trial of citalopram (20-40 g) together with 0.5 mg of vitamin B12, 2 mg of folic acid and 25 mg of vitamin B6 for 52 weeks (Australian and New Zealand Clinical Trials Registry: 12609000256279).
  • Participants were community-dwelling adults aged 50 years or over with DSM-IV-TR major depression.
  • The authors measured severity of symptoms with the Montgomery-Åsberg Depression Rating Scale (MADRS).
  • The primary outcome was remission of the depressive episode after 12, 26 and 52 weeks.
  • Secondary outcomes included reduction of MADRS scores over time and relapse of major depression after recovery by week 12.

Results
  • In total, 153 people were randomised (76 placebo, 77 vitamins).
  • Remission of symptoms was achieved by 78.1 and 79.4% of participants treated with placebo and vitamins by week 12 (P = 0.840), by 76.5 and 85.3% at week 26 and 75.8 and 85.5% at week 52 (effect of intervention over 52 weeks: odds ratio (OR) = 2.49, 95% CI 1.12-5.51).
  • Group differences in MADRS scores over time were not significant (P = 0.739).
  • The risk of subsequent relapse among those who had achieved remission of symptoms at week 12 was lower in the vitamins than placebo group (OR = 0.33, 95% CI 0.12-0.94).



Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Psychiatry

>> Click here to see the complete list
No comments:

Interesting Article from MDLinx

MDLinx  Psychiatry

5 minutes to stay current

Your Article Summary

Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up
Psychiatry Research, 12/03/14
Peselow ED, et al. – This study aims at examining the prophylactic effectiveness of four commonly used SSRIs in MDD in a naturalistic setting with long-term follow-up, the effect of concomitant Cognitive Behavioral Therapy (CBT), and the predictors of outcome. The preliminary data may help in defining the clinical utility of antidepressants and CBT in the prophylaxis of MDD.
Methods
  • In a prospective cohort study, 387 patients who either remitted or responded following treatment with four different SSRIs - fluoxetine, escitalopram, sertraline and paroxetine - were followed up over several years.

Results
  • During an average follow-up period of 34.5 months, 76.5% of patients experienced MDD recurrence.
  • Escitalopram and fluoxetine showed a numerically higher prophylactic efficacy than paroxetine and sertraline but the difference was insignificant.
  • Concluding limited prophylaxis effectiveness for SSRI-only treatment, with a recurrence rate of 82.0%.
  • Compared to 59.0% of patient recurrence rate in concomitant CBT increased prophylactic efficacy of antidepressant treatment.
  • The relatively small size of the CBT and the lack of randomization may undermine the extrapolation of its findings to clinical practice.



Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Psychiatry

>> Click here to see the complete list
No comments:

inregistare curs Psihopatologie prof.dr. A.Romila - ARTTERAPIA (09.01.2015)

No comments:

The British Journal of Psychiatry Highlights of this issue for 1 January 2015; Vol. 206, No. 1


The British Journal of Psychiatry
BJP Online -- Highlights of the Current Issue

January 2015; Vol. 206, No. 1 
The complete Table of Contents for the current issue is available online at: http://bjp.rcpsych.org/content/vol206/issue1/
  The following content is available online at: http://bjp.rcpsych.org/cgi/content/full/206/1/A3
No comments:

The British Journal of Psychiatry Table of Contents for January 2015; Vol. 206, No. 1



The British Journal of Psychiatry
Highlights of This Issue
Highlights of this issue
Sukhwinder S. Shergill
BJP January 2015 206:A3; doi:10.1192/bjp.206.1.A3

EDITORIALS
Can psychedelic compounds play a part in drug dependence therapy?
Ben Sessa and Matthew W. Johnson
BJP January 2015 206:1-3; doi:10.1192/bjp.bp.114.148031

Making a medicine out of MDMA
Ben Sessa and David Nutt
BJP January 2015 206:4-6; doi:10.1192/bjp.bp.114.152751
REVIEW ARTICLE
Efficacy of cognitive bias modification interventions in anxiety and depression: meta-analysis
Ioana A. Cristea, Robin N. Kok, and Pim Cuijpers
BJP January 2015 206:7-16; doi:10.1192/bjp.bp.114.146761

PAPERS
Positive attributes in children and reduced risk of future psychopathology
Pablo Vidal-Ribas, Robert Goodman, and Argyris Stringaris
BJP January 2015 206:17-25; doi:10.1192/bjp.bp.114.144519 OPEN ACCESS ARTICLE

Intergenerational transmission of psychopathy and mediation via psychosocial risk factors
Katherine M. Auty, David P. Farrington, and Jeremy W. Coid
BJP January 2015 206:26-31; doi:10.1192/bjp.bp.114.151050

Word use in first-person accounts of schizophrenia
S. K. Fineberg, S. Deutsch-Link, M. Ichinose, T. McGuinness, A. J. Bessette, C. K. Chung, and P. R. Corlett
BJP January 2015 206:32-38; doi:10.1192/bjp.bp.113.140046

Invited commentary on . . . Word use in first-person accounts of schizophrenia
Edgar Jones
BJP January 2015 206:39-40; doi:10.1192/bjp.bp.114.149476

Differences in voice-hearing experiences of people with psychosis in the USA, India and Ghana: interview-based study
T. M. Luhrmann, R. Padmavati, H. Tharoor, and A. Osei
BJP January 2015 206:41-44; doi:10.1192/bjp.bp.113.139048

Sadness and mild cognitive impairment as predictors for interferon-alpha-induced depression in patients with hepatitis C
Susanne Sarkar, Rahul Sarkar, Thomas Berg, and Martin Schaefer
BJP January 2015 206:45-51; doi:10.1192/bjp.bp.113.141770

Insulin resistance and outcome in bipolar disorder
Cynthia V. Calkin, Martina Ruzickova, Rudolf Uher, Tomas Hajek, Claire M. Slaney, Julie S. Garnham, M. Claire O'Donovan, and Martin Alda
BJP January 2015 206:52-57; doi:10.1192/bjp.bp.114.152850

Recovery-focused cognitive–behavioural therapy for recent-onset bipolar disorder: randomised controlled pilot trial
Steven H. Jones, Gina Smith, Lee D. Mulligan, Fiona Lobban, Heather Law, Graham Dunn, Mary Welford, James Kelly, John Mulligan, and Anthony P. Morrison
BJP January 2015 206:58-66; doi:10.1192/bjp.bp.113.141259 OPEN ACCESS ARTICLE

Speed of remission in elderly patients with depression: electroconvulsive therapy v. medication
Harm-Pieter Spaans, Pascal Sienaert, Filip Bouckaert, Julia F. van den Berg, Esmée Verwijk, King H. Kho, Max L. Stek, and Rob M. Kok
BJP January 2015 206:67-71; doi:10.1192/bjp.bp.114.148213

Last wills and testaments in a large sample of suicide notes: implications for testamentary capacity
Mark Sinyor, Ayal Schaffer, Ian Hull, Carmelle Peisah, and Kenneth Shulman
BJP January 2015 206:72-76; doi:10.1192/bjp.bp.114.145722

SHORT REPORT
Gross morphological brain changes with chronic, heavy cannabis use
Valentina Lorenzetti, Nadia Solowij, Sarah Whittle, Alex Fornito, Dan I. Lubman, Christos Pantelis, and Murat Yücel
BJP January 2015 206:77-78; doi:10.1192/bjp.bp.114.151407

CORRESPONDENCE
Can we predict switch from unipolar depression to bipolar disorder?
Genichi Sugihara and Aran Tajika
BJP January 2015 206:79; doi:10.1192/bjp.206.1.79

Authors' reply
Zezhi Li, Chen Zhang, and Yiru Fang
BJP January 2015 206:79-80; doi:10.1192/bjp.206.1.79a

CORRECTION
Correction
BJP January 2015 206:80; doi:10.1192/bjp.206.1.80

BOOK REVIEWS
Cultural Consultation: Encountering the Other in Mental Health Care
Micol Ascoli
BJP January 2015 206:81; doi:10.1192/bjp.bp.113.138313

The Art of Narrative Psychiatry: Stories of Art and Meaning
Charley Baker
BJP January 2015 206:81-82; doi:10.1192/bjp.bp.114.144626

Carl Jung (Critical Lives series)
Adam Polnay
BJP January 2015 206:82; doi:10.1192/bjp.bp.114.150466

Forensic Psychiatry: Clinical, Legal and Ethical Issues (2nd edn)
Tom Clark
BJP January 2015 206:82-83; doi:10.1192/bjp.bp.114.150524

KALEIDOSCOPE
Kaleidoscope
Derek K. Tracy, Dan W. Joyce, and Sukhwinder S. Shergill
BJP January 2015 206:85-86; doi:10.1192/bjp.206.1.85

EXTRAS
Léon Bonvin – fallen stars
Raymond Cavanaugh, Jr
BJP January 2015 206:6; doi:10.1192/bjp.bp.113.141879

Watchmen's Rorschach – psychiatry in the movies
Joseph Kane
BJP January 2015 206:25; doi:10.1192/bjp.bp.113.142125

Biological psychiatry – in 100 words
Philip Cowen
BJP January 2015 206:31; doi:10.1192/bjp.bp.113.133470

On Persuasion and Healing: A Comparative Study of Psychotherapy (1961), by Jerome D. Frank – reflection
Scott Henderson
BJP January 2015 206:38; doi:10.1192/bjp.bp.113.138677

FROM THE EDITOR'S DESK
From the Editor's desk
Kamaldeep Bhui
BJP January 2015 206:87-88; doi:10.1192/bjp.206.1.87

No comments: